SCHEMBL513766

SCHEMBL513766

CCC(CC)(c1cc(-c2cccs2)n(C)n1)P(=O)(O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
KDM4E B2RXH2 7/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
RAB9A P51151 3/20 0.37
HTT P42858 3/20 0.37
HPGD P15428 3/20 0.37
LMNA P02545 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513238 0.78 SMN1; SMN2 (0.41) ALDH1A1KDM4EL3MBTL1RAB9AHTT
SCHEMBL513979 0.76 TDP1 (0.40) ALDH1A1KDM4EL3MBTL1RAB9AHTT
SCHEMBL512797 0.75 KDM4E (0.47) ALDH1A1KDM4ERAB9AHTTHPGD
SCHEMBL4548038 0.74 KDM4E (0.51) ALDH1A1KDM4EL3MBTL1HDAC3HDAC4
SCHEMBL4548028 0.74 KDM4E (0.58) ALDH1A1KDM4EL3MBTL1HDAC3HDAC4
SCHEMBL514009 0.72 HDAC1 (0.48) ALDH1A1KDM4EL3MBTL1HDAC3HDAC4
SCHEMBL27423832 0.69 ALDH1A1 (0.46) ALDH1A1KDM4EL3MBTL1HDAC3HDAC4
SCHEMBL513361 0.69 FYN (0.41) ALDH1A1KDM4EL3MBTL1HPGDLMNA
SCHEMBL570365 0.68 PIM1 (0.54) ALDH1A1KDM4EL3MBTL1HTTHPGD
SCHEMBL2050232 0.68 SREBF2 (0.43) ALDH1A1KDM4EL3MBTL1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 ALDH1A1 2610/4885KDM4E 3490/4885L3MBTL1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.